An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety.
about
Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitorsBlocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementComparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.ptComparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registryPrognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritisTreatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab.Infliximab is equivalently suppressing oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.
P2860
Q26824970-37D3CE9A-174A-4B39-8E05-1D282133213BQ27021115-9D8B9B71-7E21-4C69-AFBF-138F51D43592Q30956564-7E0A625E-3ADA-40D4-81D5-D978E1738E28Q33778719-7AF0A929-5F08-43FF-9FF1-5A0DD9CB4E2DQ35258244-11BC6499-A572-4716-BBF1-FF9492F725FFQ35728708-D4C2167A-1155-40C0-AF9B-D61B34F98C86Q37622219-0AB79D31-F60A-4192-9A44-D205AB38C128Q40169531-CF3F468B-811F-4E9F-81F2-3C21D824A253Q43444262-1CD53C88-8478-4502-BA95-DD7E9489D28EQ43752980-36F2AE15-2943-4CCC-B9A0-0E82C694F899Q51364675-1EC244BE-C352-47E5-AA2C-B43E353AEF11Q51741859-03595017-6655-49E7-AEE4-0FD06FB7980C
P2860
An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
An observational study of toci ...... ilar drug survival and safety.
@ast
An observational study of toci ...... ilar drug survival and safety.
@en
type
label
An observational study of toci ...... ilar drug survival and safety.
@ast
An observational study of toci ...... ilar drug survival and safety.
@en
prefLabel
An observational study of toci ...... ilar drug survival and safety.
@ast
An observational study of toci ...... ilar drug survival and safety.
@en
P2093
P2860
P356
P1433
P1476
An observational study of toci ...... milar drug survival and safety
@en
P2093
Gautam A Deshpande
Hideto Oshikawa
Kazuo Matsui
Makiko Kimura
Masako Utsunomiya
Mitsumasa Kishimoto
Tatsuo Kobayashi
Yasuharu Tokuda
P2860
P304
P356
10.1093/RHEUMATOLOGY/KER295
P577
2011-09-02T00:00:00Z